PREDICTIVE FACTORS FOR LOSS OF RESPONSE TO ANTI-TNF IN CROHN’S DISEASE
ABSTRACT Background: Anti-TNF drugs are a fundamental part of the treatment of Crohn’s disease (CD), so identifying factors related to loss of response is of great importance in clinical practice. Aim: Identify potential factors related to loss of response to anti-TNF agents in Crohn’s disease patients. Methods: This is a prospective study of CD patients attending a specialized outpatient clinic using a specific form, including patients with more than one year of follow-up on anti-TNF (Infliximab, Adalimumab or Certolizumab pegol). The information obtained was tabulated and analyzed to identify possible reasons for the loss of response to anti-TNF agents; results were submitted to statistical analysis by chi-square teste considering significant p<0.05. Results: Sixty-four patients were included, most of them females (56.3%), predominant age group between 26 and 55 years, of whom 25 required optimization, 23 remained in remission with the usual dose and interval, and 16 required switch; most of those who needed switch had hematological problems such as anemia and/or had already undergone surgical treatment for CD. Conclusions: Anemia and prior CD surgery have been linked to loss of anti-TNF response..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:33 |
|---|---|
| Enthalten in: |
ABCD: Arquivos Brasileiros de Cirurgia Digestiva - 33(2020), 2 |
| Sprache: |
Englisch ; Portugiesisch |
|---|
| Beteiligte Personen: |
Byanca Rossetti Moreira dos SANTOS [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
Adalimumab |
|---|
| doi: |
10.1590/0102-672020200002e1522 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ063036304 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ063036304 | ||
| 003 | DE-627 | ||
| 005 | 20230309024427.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1590/0102-672020200002e1522 |2 doi | |
| 035 | |a (DE-627)DOAJ063036304 | ||
| 035 | |a (DE-599)DOAJb6115cefb7ff4e69b548de2a8ee3986e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng |a por | ||
| 050 | 0 | |a RD1-811 | |
| 050 | 0 | |a RC799-869 | |
| 100 | 0 | |a Byanca Rossetti Moreira dos SANTOS |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PREDICTIVE FACTORS FOR LOSS OF RESPONSE TO ANTI-TNF IN CROHN’S DISEASE |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a ABSTRACT Background: Anti-TNF drugs are a fundamental part of the treatment of Crohn’s disease (CD), so identifying factors related to loss of response is of great importance in clinical practice. Aim: Identify potential factors related to loss of response to anti-TNF agents in Crohn’s disease patients. Methods: This is a prospective study of CD patients attending a specialized outpatient clinic using a specific form, including patients with more than one year of follow-up on anti-TNF (Infliximab, Adalimumab or Certolizumab pegol). The information obtained was tabulated and analyzed to identify possible reasons for the loss of response to anti-TNF agents; results were submitted to statistical analysis by chi-square teste considering significant p<0.05. Results: Sixty-four patients were included, most of them females (56.3%), predominant age group between 26 and 55 years, of whom 25 required optimization, 23 remained in remission with the usual dose and interval, and 16 required switch; most of those who needed switch had hematological problems such as anemia and/or had already undergone surgical treatment for CD. Conclusions: Anemia and prior CD surgery have been linked to loss of anti-TNF response. | ||
| 650 | 4 | |a Crohn disease | |
| 650 | 4 | |a Infliximab | |
| 650 | 4 | |a Adalimumab | |
| 650 | 4 | |a Treatment Failure | |
| 653 | 0 | |a Surgery | |
| 653 | 0 | |a Diseases of the digestive system. Gastroenterology | |
| 700 | 0 | |a Carlos Henrique Marques dos SANTOS |e verfasserin |4 aut | |
| 700 | 0 | |a Vitória Rossetti Moreira dos SANTOS |e verfasserin |4 aut | |
| 700 | 0 | |a Claudia Yanina Garcia TORREZ |e verfasserin |4 aut | |
| 700 | 0 | |a Daniel PALOMARES-JUNIOR |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t ABCD: Arquivos Brasileiros de Cirurgia Digestiva |d Colégio Brasileiro de Cirurgia Digestiva, 2012 |g 33(2020), 2 |w (DE-627)DOAJ000075787 |x 01026720 |7 nnns |
| 773 | 1 | 8 | |g volume:33 |g year:2020 |g number:2 |
| 856 | 4 | 0 | |u https://doi.org/10.1590/0102-672020200002e1522 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/b6115cefb7ff4e69b548de2a8ee3986e |z kostenfrei |
| 856 | 4 | 0 | |u http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-67202020000200312&tlng=en |z kostenfrei |
| 856 | 4 | 0 | |u http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0102-67202020000200312&tlng=pt |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/0102-6720 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 33 |j 2020 |e 2 | ||